# Patient Care Plan

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Rachel Carson (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML041-SYN-TD
- Date: 1960-03-09
- Fictional facility: St. Posthumous Health Center
- Fictional author: Margaret Vance-Okonkwo, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

## What we are working on

- A firm lump in the left breast she found two weeks ago **S**
- Wants to be told plainly and in person what any test shows, to see the reports herself, and to make her own decisions; asks that her health be shared only with the people she chooses **S**
- Worried that illness will keep her from finishing her book **S**

## Your goals

- Receive the biopsy result in person within ten days, explained in plain words, with a copy of the report. Target: 1960-03-18. Recorded outcome: Told the diagnosis in person nine days after presentation, with the pathology report in hand; teach-back confirmed her understanding. **S**
- Make each treatment decision herself after hearing the options, benefits, and harms. Target: 1960-04-20. Recorded outcome: Chose breast-conserving surgery and, after the pathology, radiation, letrozole, ribociclib, and zoledronic acid. **S**
- Complete surgery and radiation, then start endocrine therapy, within four months of diagnosis. Target: 1960-06-15. Recorded outcome: Lumpectomy at three weeks, radiation completed at ten weeks, letrozole and ribociclib started at thirteen weeks. **S**
- Take adjuvant systemic therapy safely, with every safety check the drugs require done on schedule. Target: 1960-12-07. Recorded outcome: Ribociclib started with QTcF 418 ms; blood counts and liver tests on schedule; the day-14 ECG was late, as recorded. **S**
- Keep writing at least four mornings a week through treatment. Target: 1960-12-07. Recorded outcome: Writing most mornings, with radiation booked in the afternoons. **S**

## What we agreed to do

- Diagnostic mammography and ultrasound of the left breast and axilla this week, then image-guided core biopsy with ER, PR, HER2, and Ki-67 testing. Guideline: NCCN Clinical Practice Guidelines in Oncology: Breast Cancer, Version 5.2025 (2025); CMID: Clinical Monitoring Intelligence Database, breast cancer monograph (2026) **S**
- Breast surgical oncology consultation once the biopsy result is available, to discuss surgical options and axillary staging with her. Guideline: NCCN Clinical Practice Guidelines in Oncology: Breast Cancer, Version 5.2025 (2025) **S**
- Disclosure and shared decision-making: ask what she wants to know, give each result in person and in plain words with a written copy, check understanding by teach-back, and make every decision with her; share her health information only with the people she names. Guideline: Code of Medical Ethics Opinion 2.1.3: Withholding Information from Patients (2016); Patient-Clinician Communication: American Society of Clinical Oncology Consensus Guideline. J Clin Oncol 2017;35(31):3618-3632 (2017) **S**
- Test of cure for Helicobacter pylori by urea breath test at least four weeks after antibiotics and two weeks after stopping omeprazole. Guideline: ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J Gastroenterol 2024;119(9):1730-1753 (2024) **S**
- Knee osteoarthritis: walking and strengthening exercise, acetaminophen as needed, no nonsteroidal anti-inflammatory drugs after her ulcer. Guideline: 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee (2019) **S**
- Germline multigene panel testing with genetic counseling before surgery, as recommended for breast cancer diagnosed at 65 or younger. Guideline: NCCN Clinical Practice Guidelines in Oncology: Breast Cancer, Version 5.2025 (2025); Germline Testing in Patients With Breast Cancer: ASCO-Society of Surgical Oncology Guideline. J Clin Oncol 2024 (2024) **S**
- Left breast-conserving surgery (lumpectomy) with sentinel lymph node biopsy, her choice after mastectomy was also explained; no axillary dissection if one or two sentinel nodes are involved and she has whole-breast radiation. Guideline: NCCN Clinical Practice Guidelines in Oncology: Breast Cancer, Version 5.2025 (2025); Management of the Axilla in Early-Stage Breast Cancer: Ontario Health (Cancer Care Ontario) and ASCO Guideline. J Clin Oncol 2021;39(27):3056-3082 (2021) **S**
- Hypofractionated whole-breast and regional nodal radiation with a tumor-bed boost by the radiation oncology team, booked in the afternoons so she can write in the mornings. Guideline: NCCN Clinical Practice Guidelines in Oncology: Breast Cancer, Version 5.2025 (2025) **S**
- Letrozole 2.5 mg daily for at least five years with ribociclib 400 mg on days 1 to 21 of each 28-day cycle for three years, chosen by her; no chemotherapy with a recurrence score of 17; ECG before starting and about day 14, blood counts and liver tests every two weeks for two cycles and then at the start of the next four cycles, and electrolytes at the start of the first six cycles; avoid drugs that prolong the QT interval. Guideline: NCCN Clinical Practice Guidelines in Oncology: Breast Cancer, Version 5.2025 (2025); Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update (2019); Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer-Cyclin-Dependent Kinase 4 and 6 Inhibitors: ASCO Guideline Rapid Recommendation Update. J Clin Oncol 2024;42(18):2233-2235 (2024); KISQALI (ribociclib) tablets: prescribing information (dosage for early breast cancer; QT, hepatotoxicity, and neutropenia monitoring) (2026) **S**
- Bone health: baseline DXA, dental check, then zoledronic acid 4 mg every six months for three years; vitamin D and calcium from food; weight-bearing exercise; DXA every two years. Guideline: Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update. J Clin Oncol 2022;40(7):787-800 (2022); CMID: Clinical Monitoring Intelligence Database, breast cancer monograph (2026) **S**
- Survivorship care: history and examination every 3 to 6 months, a mammogram 6 to 12 months after radiation and then yearly, no routine tumor markers or body imaging; lymphedema checks, joint-pain and hot-flash review, distress screening, and a written survivorship care plan. Guideline: American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. CA Cancer J Clin 2016;66(1):43-73 (2016); Breast Cancer Follow-Up and Management After Primary Treatment: ASCO Clinical Practice Guideline Update. J Clin Oncol 2013;31(7):961-965 (2013); CMID: Clinical Monitoring Intelligence Database, breast cancer monograph (2026) **S**

## Follow-up

- 1960-03-09: Primary care visit for a new left breast lump; follow-up of a recently treated duodenal ulcer **S**
- 1960-03-18: Disclosure of the biopsy diagnosis of breast cancer and shared decision-making, with the breast surgical oncology consultation the same day **S**
- 1960-04-20: Review two weeks after lumpectomy and sentinel node biopsy: full disclosure of the pathology and the adjuvant treatment decision **S**
- 1960-06-15: Start of letrozole, ribociclib, and zoledronic acid after radiation **S**
- 1960-09-08: Monitoring visit at the start of the fourth ribociclib cycle **S**
- 1960-10-13: Adult preventive visit **S**

This teaching document does not replace care from a qualified clinician.
